Biological characterization of social phobia

  • Cherri M. Miner
  • Jonathan R. T. Davidson


As social phobia has become clinically more clearly characterized, the search for biologic features of the disorder has been instituted. As with most psychiatric disorders, this undertaking is difficult, because of the heterogeneity of the disorder in affected individuals. However, with investigation into several different areas, i.e., the neuroendocrine system, neurotransmitter function via naturalistic challenges, chemical and pharmacologic probes, response to pharmacologic interventions, and neuroimaging, theories about the biologic characteristics of social phobia have been advanced. Neuroendocrine studies have not yet revealed any clear abnormalities specific to individuals with social phobia. Based on studies of neurotransmitter functions and pharmacologic response, the major neurotransmitter systems that have been implicated are the serotonergic, dopaminergic, and noradrenergic. Neuroimaging studies have demonstrated possible structural and metabolic differences in some patients with social phobia.

Key words

Dopamine Serotonin Neuroimaging Social phobia 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Black B, Uhde TW, Tancer ME (1992) Fluoxetine for the treatment of social phobia (letter). J Clin Psychopharmacol 12(4): 293–295Google Scholar
  2. Blier P, Montigny C de, Chaput Y (1987) Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 7:24S-35SGoogle Scholar
  3. Brantigan CO, Brantigan TA, Joseph N (1982) Effects of betablockade and beta-stimulation on stage fright. Am J Med 72: 88–94Google Scholar
  4. Davidson JRT, Boyko O, Charles HC, Krishnan KRR, Potts N, Ford S, Patterson L (1993) Magnetic resonance spectroscopy in social phobia. J Clin Psychiatry 54 (12, Suppl): 19–25Google Scholar
  5. Davidson JRT, Ford SM, Smith RD, Potts NLS (1991) Long-term treatment of social phobia with clonazepam. J Clin Psychiatry 52 (11, Suppl): 16–20Google Scholar
  6. Davidson JRT, Potts N, Richichi E, Krishnan R, Ford S, Smith R, Wilson WH (1993) Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 13: 423–428Google Scholar
  7. Desai N, Taylor-Davies A, Barnett DB (1983) The effects of diazepam and oxprenolol on short-term memory in individuals of high- and low-state anxiety. Br J Clin Pharmacol 15: 197–202Google Scholar
  8. American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders (DSM-III). American Psychiatric Association, Washington, D.C.Google Scholar
  9. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (DSM-III-R) 3rd edn revised. American Psychiatric Association, Washington, D.C.Google Scholar
  10. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders (DSM-IV) 4th edn. American Psychiatric Association, Washington, D.C.Google Scholar
  11. Dimsdale JE, Moss J (1980a) Short-term catecholamine response to psychological stress. Psychosomatic Med 42: 493–497Google Scholar
  12. Dimsdale JE, Moss J (1980b) Plasma catecholamines in stress and exercise. JAMA 243: 340–342Google Scholar
  13. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ (1991) Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry 48: 938–945Google Scholar
  14. Goldstein S (1987) Treatment of social phobia with clonidine. Biol Psychiatry 22: 369–372Google Scholar
  15. Gorman JM, Fyer MA, Goetz R, Askanazi N, Liebowitz MR, Fyer A, Kinney J, Klein DF (1988) Ventilatory physiology of patients with panic disorder. Arch Gen Psychiatry 45: 31–39Google Scholar
  16. Gottschalk LA, Stone WN, Gleser CG (1974) Peripheral versus central mechanisms accounting for antianxiety effects of propranolol. Psychosom Med 36(1): 47–56Google Scholar
  17. Hartley LR, Ungapen S, Davies I, Spencer DJ (1983) The effect of beta adrenergic blocking drugs on speakers' performance and memory. Br J Psychiatry 142: 512–517Google Scholar
  18. James IM, Burgoyne W, Savage IT (1983) Effect of pindolol on stress-related disturbances of musical performance: preliminary communication. J Soc Med 76: 194–196Google Scholar
  19. James IM, Griffith DN, Pearson RM, Newby P (1977) Effects of oxprenolol on stage fright in musicians. Lancet 2: 952–954Google Scholar
  20. Krishnan G (1974) Oxprenolol in the treatment of examination nerves. Scott Med J 20: 288–289Google Scholar
  21. Krope P, Kohrs A, Ott H, Wagner W, Fichte K (1982) Evaluating mepindolol in a test model of examination anxiety in students. Pharmacopsychiatrica 15: 41–47Google Scholar
  22. Liebowitz MR, Quitkin FM, Stewart JW (1984) Phenelzine versus imipramine in atypical depression: a preliminary report. Arch Gen Psychiatry 44: 669–677Google Scholar
  23. Liebowitz MR, Fyer AJ, Gorman JM, Dillon D, Davies S, Stein JM, Cohen BS, Klein DF (1985) Specificity of lactate infusions in social phobia versus panic disorder. Am J Psychiatry 142(8): 947–950Google Scholar
  24. Lima L (1991) Region-selective reduction of brain serotonin turnover rate and serotonin agonist-induced behavior in mice treated with clonazepam. Pharmacol Biochem Behav 39(3): 671–676Google Scholar
  25. Mikkelsen EJ, Deltor J, Cohen DJ (1981) School avoidance and social phobia triggered by haloperidol in patients with Tourette's syndrome. Am J Psychiatry 138(120): 1572–1576Google Scholar
  26. Munjack DJ, Baltazar PL, Bohn PB, Cabe DD, Appleton AA (1990) Clonazepam in the treatment of social phobia: a pilot study. J Clin Psychiatry 51(5 Suppl): 35–53Google Scholar
  27. Munjack DJ, Bruns J, Baltazar PL, Brown R, Leonard M, Nagy R, Koek R, Crocker B, Schafer S (1991) A pilot study of buspirone in the treatment of social phobia. J Anxiety Disord 5: 87–98Google Scholar
  28. Neftel KA, Adler RH, Kappell L, Rossi M, Dolder M, Kaser HE, Bruggesser HH, Vorkauf H (1982) Stage fright in musicians: a model illustrating the effects of beta blockers. Psychosom Med 44: 461–469Google Scholar
  29. Papp LA, Gorman JM, Liebowitz MR, Fyer AJ, Cohen B, Klein DF (1988) Epinephrine infusions in patients with social phobia. Am J Psychiatry 146(6): 733–736Google Scholar
  30. Potts NL, Davidson JR, Krishnan KR, Doraiswamy PM, Ritchie JC (1991) Levels of urinary-free cortisol in social phobia. J Clin Psychiatry 52 (Suppl): 41–42Google Scholar
  31. Pratt J, Lenner P, Reynolds EH, Marsden CD (1979) Clonazepam induces decreased serotonergic activity in the mouse brain. Neuropharmacology 18: 791–799Google Scholar
  32. Reich JR, Yates W (1988) A pilot study of treatment of social phobia with alprazolam. Am J Psychiatry 145(5): 590–594Google Scholar
  33. Reich JR, Noyes R, Yates W (1989) Alprazolam treatment of avoidant personality traits in social phobic patients. J Clin Psychiatry 50(3): 991–995Google Scholar
  34. Schneier FR, Chin SJ, Hollander E, Liebowitz MR (1992) Fluoxetine in social phobia (letter). J Clin Psychopharmacology 12(1): 62–63Google Scholar
  35. Schneier FR, Saoud JB, Campeas R, Fallon BA, Hollander E, Coplan J, Liebowitz MR (1993) Buspirone in social phobia. J Clin Psychopharmacol 13(4) 251–256Google Scholar
  36. Siitonen L, Jane J (1976) Effect of beta-blockade during bowling competitions. Am Clin Res 8: 393–398Google Scholar
  37. Stein MB, Tancer ME, Uhde TW (1992) Heart rate and plasma norepinephrine responsivity to orthostatic challenge in anxiety disorders. Arch Gen Psychiatry 49: 311–317Google Scholar
  38. Tancer ME (1993) Neurobiology of social phobia. J Clin Psychiatry 54 (12, Suppl): 26–30Google Scholar
  39. Tancer ME, Uhde TW (1989) Neuroendocrine, physiologic, and behavioral responses to clonidine in patients with social phobia. Biol Psychiatry 25: 189AGoogle Scholar
  40. Tancer ME, Stein MB, Uhde TW (1990a) Effects of thyrotropin-releasing hormone on blood pressure and heart rate in social phobia patients, panic disorder patients, and normal controls: results of a pilot study. Biol Psychiatry 27(7): 781–783Google Scholar
  41. Tancer ME, Stein MB, Gelernter CS, Uhde TW (1990b) The hypothalamic-pituitary-thyroid axis in social phobia. Am J Psychiatry 147: 929–933Google Scholar
  42. Tancer ME, Stein MB, Uhde TW (1991) Lactate response to caffeine in panic disorder: a replication using an “anxious” control group. Biol Psychiatry 29: 57A (Abstract)Google Scholar
  43. Uhde TW, Tancer ME (1994) Normal urinary-free cortisol and postdexamethasone cortisol in social phobia. J Affect Disord 30: 155–161Google Scholar
  44. Van Amerigen M, Mancini C, Streiner DL (1993) Fluoxetine efficacy in social phobia. J Clin Psychiatry 54(1): 27–32Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • Cherri M. Miner
    • 1
  • Jonathan R. T. Davidson
    • 1
  1. 1.Department of PsychiatryDuke University Medical CenterDurhamUSA

Personalised recommendations